Company News: Eisai and Arena Pharmaceuticals

Share this article:
Japanese drug firm Eisai made a bet on obesity last week, signing a multi-million dollar deal with Arena Pharmaceuticals for the right to sell Arena's lorcaserin weight-loss pill, if approved. The deal includes a $50-million upfront, another $160 million based on development and approval milestones and a $1.16 billion, one-time payment that may follow based on annual sales. Eisai's timing was a bit surprising considering lorcaserin doesn't face an FDA panel until September and a decision until late October. Two other developers of diet pills are hoping for FDA approval, Orexigen for Contrave and Vivus for Qnexa, and both are seeking pharmaceutical partnerships. FDA is set to decide on Contrave in December. Qnexa faces an advisory panel July 15, and the FDA is scheduled to rule on the drug in October.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.